Breaking News

Vectura, Incannex Enter Preclinical Services Agreement

Vectura to provide development services for IHL-216A, Incannex’s inhaled drug product for the treatment of traumatic brain injury.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Vectura Group plc, an inhalation CDMO, has signed an agreement with Incannex Healthcare Ltd., an Australian cannabinoid medicines development company, to provide preclinical development services for IHL-216A, Incannex’s proprietary inhaled drug product for the treatment of traumatic brain injury (TBI).   Vectura will provide formulation screening studies, manufacturing process optimization studies and stability assessments, as well as manufacturing a lab-scale batch of IHL-216A to support toxi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters